Renal dysfunction and accuracy of N-terminal pro-B-type natriuretic peptide in predicting mortality for hospitalized patients with heart failure

Circulation Journal

Volumn 78, Issue 10, 2014, Pages 2439-2446

  Scrutinio, Domenico ^a   Mastropasqua, Filippo ^a   Guida, Pietro ^a   Ammirati, Enrico ^b,c   Ricci, Vitoantonio ^a   Raimondo, Rosa ^a   Frigerio, Maria ^b   Lagioia, Rocco ^a   Oliva, Fabrizio ^b  

^a IRCCS   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Acute decompensated heart failure; Mortality; N terminal pro B type natriuretic peptide; Prognosis; Renal function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART TRANSPLANTATION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; COMPLICATION; HEART FAILURE; HOSPITALIZATION; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE;

EID: 84908260338     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0405     Document Type: Article

References (39)

1. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
2. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
3. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-Type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177-2187.
4. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839.
5. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012; 33: 2001-2006.
6. Levy WC. Can B-type natriuretic peptides replace heart failure risk models? Eur J Heart Fail 2008; 10: 224-225.
7. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T-and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-725.
8. Richards AM, Troughton RW. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012; 58: 62-71.
9. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, et al. B-Type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61: 1498-1506.
10. Januzzi JL Jr. Natriuretic peptides, ejection fraction, and prognosis: Parsing the phenotypes of heart failure. J Am Coll Cardiol 2013; 61: 1507-1509.
11. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47: 582-586.
12. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR. Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem 2007; 53: 1928-1935.
13. Christenson RH, Azzazy HM, Duh SH, Maynard S, Seliger SL, deFilippi CR. Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. Clin Chem 2010; 56: 633-641.
14. Butlet J, Chirovsky D, Phatak H, McNeill A, Cody R. Renal function, health outcomes, and resource utilization in acute heart failure: A systematic review. Circ Heart Fail 2010; 3: 726-745.
15. Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, et al. Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 2013; 77: 687-696.
16. Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013; 77: 944-951.
17. deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007; 53: 1511-1519.
18. Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005; 45: 1667-1671.
19. Palazzuoli A, Masson S, Ronco C, Maisel A. Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: The role of natriuretic peptides and troponin. Heart Fail Rev 2014; 19: 267-284.
20. Wang AY. Clinical utility of natriuretic peptides in dialysis patients. Semin Dial 2012; 25: 326-333.
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240-e319, doi:10.1161/CIR.0b013e31829 e8776.
22. Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, et al. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure: Derivation and validation of the ADHF/NT-proBNP risk score. Int J Cardiol 2013; 168: 2120-2126.
23. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
24. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27: 330-337.
25. Zou KH, O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007; 115: 654-657.
26. Royston P. Explained variation for survival models. Stata J 2006; 6: 83-96.
27. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-2174.
28. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014; 35: 455-469.
29. Givertz MM, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, et al. Renal function trajectories and clinical outcomes in acute heart failure. Circ Heart Fail 2014; 7: 59-67.
30. Carrasco-Sánchez FJ, Pérez-Calvo JI, Morales-Rull JL, Galisteo-Almeda L, Páez-Rubio I, Barón-Franco B, et al. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels. J Cardiovasc Med (Hagerstown) 2014; 15: 115-121.
31. Pencina MJ, D’Agostino RB, D’Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
32. van Kimmenade RR, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide: A mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009; 53: 884-890.
33. Leeflang MMG, Moons KGM, Reitsma JB, Zwinderman AH. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: Mechanisms, magnitude, and solutions. Clin Chem 2008; 54: 729-737.
34. Greenberg B. Acute decompensated heart failure: Treatments and challenges. Circ J 2012; 76: 532-543.
35. van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, et al. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: Redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48: 1621-1627.
36. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-573.
37. Hachamovitch R, Di Carli MF. Methods and limitations of assessing new noninvasive tests: Part II: Outcomes-based validation and reliability assessment of noninvasive testing. Circulation 2008; 117: 2793-2801.
38. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: Time for a reassessment? J Am Coll Cardiol 1999; 34: 618-620.
39. O’Connor CM, Miller AB, Blair JEA, Konstam MA, Wedge P, Bahit MC, et al. Causes of death and rehospitalizations in patients hospitalized with worsening heart failure and reduced left ventricular function: Results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010; 159: 841-849.